SCHEMBL6503346

SCHEMBL6503346

Cc1ccc(-c2ccc(OC(C)C)cc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MAOB P27338 1/20 0.45
TAS1R3 Q7RTX0 2/20 0.44
TAS1R1 Q7RTX1 2/20 0.44
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
NLRP1 Q9C000 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
CTNNB1 P35222 2/20 0.43
TCF7L2 Q9NQB0 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491534 0.93 NPC1 (0.56) HTTNPC1RAB9AMAOBMAPT
SCHEMBL6490703 0.93 NPC1 (0.48) HTTNPC1RAB9AMAOBTAS1R3
SCHEMBL6488808 0.92 AURKA (0.49) HTTNPC1RAB9AMAPTKMT2A
SCHEMBL6499260 0.92 CNR1 (0.50) NPC1RAB9AMAOBTAS1R3TAS1R1
SCHEMBL6489521 0.91 SMN1; SMN2 (0.49) HTTNPC1RAB9AMAOBTAS1R3
SCHEMBL6488795 0.90 SMO (0.50) NPC1RAB9AMAOBSMN1; SMN2
SCHEMBL6489185 0.89 TAS1R3 (0.53) HTTNPC1RAB9AMAOBTAS1R3
SCHEMBL6792042 0.89 NPC1 (0.52) HTTNPC1RAB9AMAOBTAS1R3
SCHEMBL6502209 0.88 CTNNB1 (0.50) HTTNPC1RAB9AMAOBMAPT
SCHEMBL6488828 0.88 CNR1 (0.51) HTTNPC1RAB9ATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HTT 2574/4885NPC1 100/4885RAB9A 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.